Gilead authorized sovaldi generic drugs to be sold to 91 developing countries, but no China

Source: on September 18, 2014, Gilead recently had two eye-catching events! First, Gilead will soon launch a new drug, the new generation of hepatitis C cocktail therapy LDV / sof compound tablets, with a price of up to $95000 / course More expensive than the amazing sovaldi! Second, Gilead recently reached an agreement with seven Indian imitators to produce sovaldi and LDV / sof compound tablets, which are sold to 91 developing countries at ultra-low prices, helping to promote humanitarian projects in these countries How do Americans feel sad when the two things are put together? Some media directly "joked" that Gilead, you do this, your parents know? However, you in China can only watch this at present, because sovaldi and LDV / sof compound tablets have nothing to do with China for the time being, and their generic drugs have nothing to do with China - yes, the 91 developing countries do not include China, which has a large number of hepatitis C patients So, let's continue to see how Gilead "works" in the mood of a spectator Cut prices or get kicked out of health care? Sovaldi's high price of $84000 / course of treatment has already made the payer of medical expenses in the United States, the insurance company, extremely dissatisfied It has asked for price reduction many times, but Gilead is very straight in front of them, that is to say, he will not drop However, in front of India, Gilead offered a huge discount of 0.1% The reason is very simple India has relevant laws and regulations If sovaldi does not reduce its price, Indian pharmaceutical companies can strongly imitate it In fact, the United States has expressed its dissatisfaction with sovaldi before Gilead's "one is more important than the other" Drug welfare managers in the United States (PBMs) set various restrictions on sovaldi: for example, doctors are required to delay treatment for hepatitis C patients when conditions permit, until the price of sovaldi is reduced The energy and Trade Committee of the U.S House of Representatives is sending a letter to Gilead company, asking it to establish a public price system, and what public health impact will be on public health if medical insurance companies and public health plans do not pay for all patients with hepatitis C using sovaldi One of the largest pharmacy benefit management companies in North America even warned Gilead that sovaldi's high price was intolerable and that it would appeal to all customers and clients to stop sovaldi once other similar oral drugs were approved And this "other similar oral medicine" should be on the market soon Daklnza / sovaldi, a full oral hepatitis C cocktail from BMS, has been approved Abt-450 / ritonavir / abt-267 / abt-333, developed by abbvie, has been recognized as a breakthrough therapy by FDA and is expected to be approved by the end of this year The clinical cure rate of these two cocktail therapies for genotype 1 HCV in clinical trials has reached 100% More importantly, they will probably go public at a low price to compete for market share In the near future, Gilead will either cut prices or wait to be kicked out of the insurance 91 developing countries? It's not that the market leader sovaldi still has a long patent period, but Geely de unexpectedly reached an agreement with seven generic companies to authorize the production of sovaldi generic drugs The seven generic companies are Cipla, Ranbaxy laboratories, cadilla healthcare, mylan, SEQUEST scientific, structures arcollab and hetero Their sovaldi generic will be sold in 91 developing countries, including India and Pakistan These companies can decide the price of sovaldi generics at their own discretion, but they need to pay a commission to Gilead based on the sales It is believed that the move will allow Geely to enter a broader market in developing countries, and at the same time help Geely ease criticism of its high price from the United States However, these 91 countries do not include China, the country with the largest number of hepatitis C patients in the world, and some middle-income countries with a large number of patients, such as Ukraine, Brazil, Mexico and Thailand, where 70% of the world's hepatitis C patients are said to live Obviously, Gilead has left these richer markets to itself Gilead you may not know: Gilead was founded in 1987 and its founder Riordan worked for Monroe venture capital Gilead has no income within 5 years of its establishment and no profit within 8 years During this period, Riordan's financing achievements for Gilead are as follows: US $2 million in 1988; US $10 million in 1989; US $40 million in 1991; US $86 million in 1992; US $94 million in 1995; US $160 million in 1996 From 1998 to 2001, sales revenue increased fivefold Since then, it has maintained rapid growth Rumsfeld became a director and senior consultant of Gilead in 1988 and chairman of the board of Gilead in 1997 When he resigned from Gilead to become defense minister in 2001, he had tens of millions of dollars in Gilead stock The famous anti influenza drug Tamiflu was developed and patented by Gilead Roche participated in the clinical trials and was responsible for the production, registration, listing and marketing of the drug Gilead charged 12% equity Gilead started from the "integration" of anti HIV / ADIS drugs (compound preparation, reducing the number of drugs, and even improving the drug efficacy) Currently, Gilead's drugs involve HIV / ADIS, liver diseases, tumors, cardiovascular diseases, respiratory diseases and other fields, but the largest number is still HIV / ADIS drugs